CANCER SUPPORT
1300 881 698
CANCER SUPPORT | 1300 881 698
NEW ADDITION TO PANCARE’S BOARD OF DIRECTORS 2 September 2024
Nikki Rynia
Pancare Foundation is proud to announce the appointment of Kate O’Sullivan to its Board of Directors, a strategic move that reinforces its leadership team.
Have your say on treatments that matter to you
People with Pancreatic Cancer and Oesophageal cancer are invited to share their views on two medications that are being considered at an upcoming Pharmaceutical Benefits Advisory Committee (PBAC)
February is Gallbladder and Bile Duct Cancer Awareness Month.
Chris Capstick
This year it is estimated that over 2226 Australians will be diagnosed with either gallbladder or biliary tract cancer. There is no early detection test, and there is a five-year survival rate of
Patients and their families impacted by upper gastrointestinal (GI) cancers are invited to share their lived experience on two therapies that are listed in the upcoming Pharmaceutical Benefits
Navigating the Festive Season
Has all the festive feasting got you feeling a little Bah-Humbug about the holiday season? You’re not alone. Food can bring up many challenges for someone with upper gastrointestinal cancer.
Medicines Update.
The Pharmaceutical Benefits Scheme (PBS), delivered welcomed news for Australians living with biliary cancer this week with IMFINZI® (durvalumab) being made available for patients diagnosed with
$20 million funding boost gives new hope for Australians impacted by pancreatic cancer
Pancare Foundation welcomes the Australian Government’s delivery of the Pancreatic Cancer Roadmap and the commitment of $20.3 million to support improved outcomes and survival for Australians
Creon Supply Issues
The companies who are responsible for suppling medicines in Australia do their best to maintain medicine supply. On occasion there may be issues with Creon® supply. Here are some tips about how you
Wins for pancreatic cancer clinical trials research
Pancare is delighted to have contributed to two successfully funded clinical trials for pancreatic cancer research, announced in the recent 2021 MRFF Rare Cancers and Unmet Need (RCRDUN) Clinical
A message of thanks 2021 from CEO, Doug Hawkins
As we approach the end of another year disrupted by the COVID-19 pandemic, I reflect on what has been a resounding theme for our Foundation and community – resilience in the face of adversity.
